首页> 美国卫生研究院文献>other >Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors

【2h】

Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors

机译：在妇女的组蛋白脱乙酰酶抑制剂的Belinostat的II期试验用铂耐药上皮性卵巢癌和微乳头（Lmp）卵巢肿瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

AimMicropapillary/borderline (LMP) ovarian tumors are rarely included in clinical trials and are intrinsically resistant to radiation and chemotherapy. Platinum resistant epithelial ovarian cancer (EOC) has a poor prognosis. The histone deacetylase inhibitor belinostat demonstrated antitumor activity in preclinical ovarian cancer models.

著录项

期刊名称 other
作者
Helen J. Mackay; Hal Hirte; Terrence Colgan; Al Covens; Katrina MacAlpine; Pamela Grenci; Lisa Wang; Jaqueline Mason; Pnu-An Pham; Ming-S Tsao; James Pan; James Zwiebel; Amit M. Oza;
展开▼
作者单位

展开▼
年(卷),期 -1(46),9
年度 -1
页码 1573–1579
总页数 12
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. [J] . Mackay HJ, Hirte H, Colgan T, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2010,第9期

机译：组蛋白脱乙酰基酶抑制剂belinostat在患有铂耐药性上皮性卵巢癌和微乳头（LMP）卵巢肿瘤的女性中进行的II期临床试验。
2. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [J] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, BMC Cancer . 2018,第1期

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法
3. Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer [J] . Ignace B. Vergote, Agustin Garcia, John Micha, Journal of Clinical Oncology . 2013,第32期

机译：随机多中心II期临床试验比较两种方案的依替立替康聚乙二醇（NKTR-102）在患有铂耐药/难治性上皮性卵巢癌的女性中的应用
4. The Comparison of Glycosphingolipids in an Epithelial Ovarian Cancer Cell Line and a Nontumorigenic Epithelial Ovarian Cell Line using MALDI-MS [C] . Krishani K. Rajanayake, William R. Taylor, Dragan Isailovic ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：使用MALDI-MS对上皮性卵巢癌细胞系中糖磷脂和非致素上皮性卵巢细胞系的比较
5. Anti-ovarian cancer effects of histone deacetylase inhibitors and calpain inhibitor. [D] . Lapinska, Karolina Eva. 2016

机译：组蛋白脱乙酰基酶抑制剂和钙蛋白酶抑制剂的抗卵巢癌作用。
6. Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium [O] . Isabelle Ray-Coquard, Ioana Braicu, Regina Berger, 2007

机译：GANNET53的第I部分：欧洲多中心I / II期Hsp90抑制剂Ganetespib联合每周紫杉醇治疗高级别，抗铂类上皮性卵巢癌女性的研究-GANNET53联盟的研究
7. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法

Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅